Now available in your hands: Base editing with AI-engineered precision
We have expanded our Pin-point™ base editing platform to include adenine base editors (ABEs) featuring AI-engineered adenine deaminases developed by Profluent.
These ABE reagents complement our established cytosine base editor (CBE) catalog offerings, providing researchers with comprehensive access to advanced state-of-the-art base editing technologies.
Derived from the same core platform architecture used in therapeutic development, these reagents are now available as catalog products to support your proof-of-concept studies and research initiatives.
Pin-point™ Reagents & Platform: Pin-point™ base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
Key scientific presentations at ASGCT
At ASGCT, oral presentations highlight where the field is moving.
This year, three talks reflect a clear direction: greater control, more precise targeting, and improved consistency across gene therapy workflows.
An rAAV8 reference standard defined by extensive orthogonal characterization
Reliable comparison across studies remains a major challenge in gene therapy.
This work introduces a highly characterized rAAV8 reference standard, supporting analytical consistency and long-term quality monitoring across platforms.
Want to go deeper?
Connect with Igor at ASGCT.
Session name: Advanced analytics assays
Session date and time: 05/12/2026 10:15 AM - 12:00 PM
Session room: MCEC Room 257AB (Level 2)
Presentation time: 11:30 AM - 11:45 AM
Creating novel retinal targeting rAAV capsids with scalable, clinically compatible manufacturing AAV capsid engineering approaches are enabling more precise targeting
Novel retinal AAV variants show up to 30x improved transduction, combined with scalable, clinically compatible manufacturing.
Curious how this translates to your projects?
Meet Janina at ASGCT.
Session name: AAV downstream manufacturing
Session date and time: 05/12/2026
Session room: MCEC Room 109AB (Level 1)
Presentation time: 11:30 AM - 11:45 AM
Modular base editing enables greater precision: The Pin-point™ platform for therapeutic genome engineering
As delivery becomes more precise, gene editing must follow.
The Pin-point™ platform introduces a modular approach to base editing for more controlled genome engineering.
Interested in learning more?
Join the session or connect with Amanda at ASGCT.
Session: vTools and technology forum
Wednesday May 13 9:45 am
A commercial license is required for any clinical or commercial application involving AAVs developed using Revvity technologies
Pin-point™ Reagents & Platform: Pin-point™ base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
Viral vector engineering
Nanobody-based capsid re-targeting is enabling tailored delivery to previously difficult-to-reach cell types. In neuronal models, these approaches have shown transduction efficiencies of up to 40–65%, significantly improving performance without added toxicity.
At the same time, advances in capsid evolution strategies are refining how new vectors are discovered. Comparative studies of DNA- and RNA-driven selection show differential enrichment across tissues, informing a more reliable path to tissue-specific targeting.
Beyond AAV, modular surface modification of lentiviral vectors is enabling controlled tropism while maintaining manufacturability, addressing key challenges for in vivo applications.
Together, these approaches reflect a broader shift: vector targeting is becoming a design parameter, not a limitation.
Check our posters:
AAV-Nanobody mediated improvement in transduction of human iPSC-derived NGN2 and AD2 neuronal cells
Abstract ID: 2036
Presentation Day: 05/13/2026
Poster Reception: 5:00 PM - 6:30 PM
Comparative Analysis of RNA-Driven vs. DNA-Driven AAV Capsid Evolution Strategies for CNS and Bone Targeting
Abstract ID: 1030
Presentation Day: 05/12/2026
Poster Reception: 5:00 PM - 6:30 PM
Beyond broad tropism: A modular surface modification platform for targeted lentiviral vectors
Abstract ID: 3065
Presentation Day: 05/14/2026
Poster Reception: 5:00 PM - 6:30 PM
Abstract ID: 2036
Presentation Day: 05/13/2026
A commercial license is required for any clinical or commercial application involving AAVs developed using Revvity technologies.
Viral vector manufacturing
As gene therapies move toward scale, manufacturing becomes a critical point of control.
The challenge is no longer only to produce vectors-but to do so consistently, efficiently, and at scale.
Design of Experiments (DoE) approaches are enabling a more systematic way to optimize production. By reducing thousands of possible conditions to a focused design space, these strategies have demonstrated up to ~2.8x increases in productivity while maintaining functional performance.
At the same time, upstream steps such as plasmid amplification are being refined to balance sequence fidelity and yield. New workflows using optimized E. coli strains show improved ITR integrity while maintaining scalability, addressing a key bottleneck in AAV manufacturing.
Automation is also transforming how vector libraries are produced, enabling high-throughput generation of hundreds of variants with improved consistency and reduced hands-on variability.
Finally, integrated production platforms combining optimized cell lines and transgene control strategies are improving both yield and robustness, with significant gains for difficult or cytotoxic payloads.
Together, these approaches reflect a broader shift: manufacturing is becoming a controlled and predictable process, not a limiting factor.
Check our posters:
rAAV-Nanobody manufacturing optimization through Design of Experiments (DoE) and functional analysis
Abstract ID: 3140
Presentation Day: 05/14/2026
Poster Reception: 5:00 PM - 6:30 PM
Evaluating E. coli JW0387 for scalable, Universal AAV transfer plasmid Amplification: Balancing ITR fidelity and productivity
Abstract ID: 3147
Presentation Day: 05/14/2026
Poster Reception: 5:00 PM - 6:30 PM
Automating rAAV Library Production for NextGen Capsid Discovery
Abstract ID: 2039
Presentation Day: 05/13/2026
Poster Reception: 5:00 PM - 6:30 PM
Enhanced Full Capsid Yield and Transgene Expression Control in rAAV Production Using HEKcellence™ and Vectonize™ Technologies
Abstract ID: 3142
Presentation Day: 05/14/2026
Poster Reception: 5:00 PM - 6:30 PM
For research use only. Not for use in diagnostic procedures.
HEKcellence™ platform and Vectonize™ technology are available for research, clinical, and commercialization applications, including services, under specific limited licenses from Revvity A commercial license is required for any clinical or commercial application involving AAVs developed using Revvity technologies.
Viral vectors analytics
One of the biggest challenges in gene therapy is not only performance, but predictability.
Understanding how vectors behave in human-relevant systems remains critical to reducing translational risk.
Advanced liver microphysiological systems (MPS) are enabling a more comprehensive view of AAV behavior. By replicating key features of human liver architecture, these models allow simultaneous assessment of transduction efficiency, cellular tropism, and hepatotoxicity over time.
This approach provides a more physiologically relevant alternative to traditional models, capturing both efficacy and safety signals within the same system.
As gene therapies become more complex, these platforms offer a critical advantage: the ability to better predict in vivo outcomes before reaching the clinic.
Check our poster:
A novel in vivo-like liver MPS enables multi-dimensional assessment of AAV performance and hepatotoxicity over an extended culture period
Abstract ID: 3241
Presentation Day: 05/14/2026
Poster Reception: 5:00 PM - 6:30 PM
For research use only. Not for use in diagnostic procedures.
Designing the next generation of gene editing
Modular base editing approaches are enabling a new level of control over genome engineering workflows. By decoupling key components such as Cas and deaminase activity, these systems allow independent tuning of editing efficiency, specificity, and off-target effects.
This flexibility extends to complex applications, where multiplex gene editing and precise transgene integration can be achieved simultaneously, without compromising cell viability or genomic stability.
Combined with sequence-aware design strategies and adaptable delivery formats, these approaches are shifting gene editing from empirical optimization toward more predictable, design-driven systems.
Together, they point to a broader evolution: precision in gene editing is no longer fixed, it is tunable.
Check our poster:
Decoupling deaminase recruitment reveals a Cas association-dependent origin of off-target base editing
Session welcome and poster reception
05/12/2026 ET
Sequence-context–aware design of precision base editors using modular architectures enables scalable therapeutic gene correction
Session welcome and poster reception
05/12/2026 ET
Decoupling deaminase recruitment and transgene targeting resolves tradeoffs in multiplexed base editing workflows
Session poster reception
05/13/2026 ET
Modular lipid nanoparticle delivery of base editor components enables versatile platform strategies for therapeutic genome editing
Session poster reception 05/14/2026 ET
Pin-point™ Reagents & Platform: Pin-point™ base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
Our CGT ecosystem - Built for your journey
Identifying and validating disease-relevant genetic targets while facilitating efficient screening, cell characterization, and early gene editing-without compromising data quality or speed.
Delivering therapeutic payloads efficiently into target cells, while reducing toxicity, immune response, and variability across viral and non-viral systems.
Bridging the gap between discovery and clinical trials requires robust tools to assess viability, expression, toxicity, and mechanism of action-across increasingly complex 3D models and in vivo systems.
Moving from small-scale experiments to clinical-grade production requires optimized processes, GMP-aligned reagents, and consistent vector performance-all while maintaining speed and regulatory readiness.
Helping every batch to meet regulatory expectations for identity, purity, potency, and stability—while streamlining testing workflows and reducing delays.
Our CGT ecosystem - tailored for your therapy type
InVivo Gene Therapy
In vivo gene therapy delivers genetic material directly into the patient’s cells—typically using viral vectors such as AAV or lipid nanoparticles. These therapies are often designed for long-term or permanent correction with a single administration.
In vivo gene therapy delivers genetic material directly into the patient’s cells—typically using viral vectors such as AAV or lipid nanoparticles. These therapies are often designed for long-term or permanent correction with a single administration.
Ex vivo Gene Therapy
Ex vivo gene therapy involves harvesting a patient’s cells, genetically modifying them in vitro, and then re-infusing them. It facilitates tighter control over editing and characterization, often used in hematologic or immune-based therapies.
Ex vivo gene therapy involves harvesting a patient’s cells, genetically modifying them in vitro, and then re-infusing them. It facilitates tighter control over editing and characterization, often used in hematologic or immune-based therapies.
Cell Therapy
Cell therapy leverages the body’s natural cellular abilities to address complex health challenges, without altering the genetic makeup of the cells.
Cell therapy leverages the body’s natural cellular abilities to address complex health challenges, without altering the genetic makeup of the cells.
Meet our experts
